A Phase 1 interventional study of brivaracetam in Healthy Participants, sponsored by UCB Biopharma SRL. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-13.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 30th largest by enrollment, is one of 3 that started in 2021, is one of 6 in phase 1, and was the 29th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2021.
This study's enrollment of 12 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 105th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2021, is one of 7 in phase 1, and was the 126th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the pharmacokinetics, safety, and tolerability of brivaracetam after a single dose and multiple doses in healthy adult Chinese Study Participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a Single-Arm study with Single- and Multiple- Dose Periods. Study participants will receive a single dose of brivaracetam (BRV) on Day 1 and will then receive multiple doses of brivaracetam from Day 5-10.
Drug: brivaracetam
* Pharmaceutical form: Film-coated tablets * Concentration: 100 mg tablets * Route of administration: Oral use
Also known as: Briviact
Plasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Single Dose
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Plasma Concentration of BRV and Its Metabolites (Ucb-42145, Ucb-100406-1, ucb107092-1) After Multiple Dose
Time frame: Predose on Day 5, 6, 7, 8, and 9; Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measured Concentration Above the Limit of Quantification (AUC(0-t)) of Brivaracetam for Single Dose
AUC(0-t) was defined as the area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Maximum Observed Plasma Concentration (Cmax) of Brivaracetam for Single Dose
Cmax was defined as the maximum observed plasma concentration.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Area Under the Plasma Concentration-time Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Brivaracetam for Multiple Dose
AUC(0-12),ss was defined as the area under the plasma concentration-time curve from 0 to 12 hours at steady state.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours postdose
Maximum Plasma Concentration at Steady State (Cmax,ss) of Brivaracetam for Multiple Dose
Cmax,ss was defined as the maximum plasma concentration at steady state.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent AEs (TEAEs) were defined as those events that start on or after the time of first investigational medicinal product (IMP) administration, or whose severity worsens on or after the date of first administration of the IMP.
Time frame: From Baseline to the end of Safety Follow-up (approximately 6 weeks)
Time to Reach Maximum Concentration (Tmax) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose
Tmax was defined as the time to reach maximum concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Terminal Elimination Half-life (t1/2) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose
t1/2 was defined as the terminal elimination half-life. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Rate Constant of Elimination (λz) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose
λz was defined as the rate constant of elimination. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Mean Residence Time (MRT) of Brivaracetam in Plasma for Single Dose
MRT was defined as the mean residence time.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Area Under the Plasma Concentration-time Curve From 0 to Infinite Time (AUC) of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 for Single Dose
AUC was defined as the area under the plasma concentration-time curve from 0 to infinite time. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Apparent Total Body Clearance (CL/F) of Brivaracetam in Plasma for Single Dose
CL/F was defined as the apparent total body clearance.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Apparent Volume of Distribution (Vz/F) of Brivaracetam in Plasma for Single Dose
Vz/F was defined as the apparent volume of distribution.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Cmax of Ucb-42145, Ucb-100406-1 and ucb107092-1 for Single Dose
Cmax was defined as the maximum plasma concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
AUC (0-t) of Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Single Dose
AUC(0-t) was defined as the area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Tmax of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose
tmax is the time to reach maximum plasma concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
t1/2 of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose
t1/2 is the terminal elimination half-life. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
λz of Brivaracetam, Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose
λz is the rate constant of elimination. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Minimum Plasma Concentration at Steady State (Cmin,ss) of Brivaracetam in Plasma for Multiple Dose
Cmin,ss is the minimum plasma concentration at steady state.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Average Plasma Concentration at Steady State (Cav,ss) of Brivaracetam in Plasma for Multiple Dose
Cav,ss is the average plasma concentration at steady state.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Apparent Total Body Clearance at Steady State (CLss/F) of Brivaracetam in Plasma for Multiple Dose
CLss/F is the apparent total body clearance at steady state.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Vz/F of Brivaracetam in Plasma for Multiple Dose
Vz/F is the apparent volume of distribution.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Cmax,ss of Ucb-42145, Ucb-100406-1, and ucb107092-1 in Plasma for Multiple Dose
Cmax,ss is the maximum plasma concentration at steady state. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Area Under the Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Ucb-42145, Ucb-100406-1 and ucb107092-1 in Plasma for Multiple Dose
AUC(0-12),ss is the area under the curve from 0 to 12 hours at steady state. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours postdose
Peak Trough Fluctuation (PTF) of Brivaracetam in Steady-state for Multiple Dose
PTF was calculated as (Cmax,ss-Cmin,ss)/Cav,ss.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
Accumulation Ratio Calculated From AUC at Steady State and AUC After Single Dose (RAUC) of Brivaracetam for Multiple Dose
Accumulation ratio (RAUC) was calculated as AUC(0-12),ss divided by AUC(0-12).
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours postdose
Accumulation Ratio Calculated From Cmax at Steady State and Cmax After Single Dose (Rmax) of Brivaracetam for Multiple Dose
Accumulation ratio (Rmax) was calculated as Cmax,ss divided by Cmax.
Time frame: Day 10: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, and 72 hours postdose
The study started to enroll study participants in May 2021 and concluded in June 2021.
| Milestone | Brivaracetam |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
| nanograms/milliliter (ng/mL) | Brivaracetam |
|---|---|
| BRV- Day 1: Predose | NA ± NA |
| BRV- Day 1: 0.25 hour postdose | 1039 ± 134 |
| BRV- Day 1: 0.50 hour postdose | 2610 ± 46.2 |
| BRV- Day 1: 1 hour postdose | 2725 ± 19.6 |
| BRV- Day 1: 1.5 hours postdose | 2458 ± 15.9 |
| BRV- Day 1: 2 hours postdose | 2602 ± 18.2 |
| BRV- Day 1: 3 hours postdose | 2387 ± 21.3 |
| BRV- Day 1: 4 hours postdose | 2181 ± 22.8 |
| BRV- Day 1: 6 hours postdose | 1793 ± 22.4 |
| BRV- Day 1: 9 hours postdose | 1389 ± 27.8 |
| BRV- Day 1: 12 hours postdose | 1064 ± 28.8 |
| BRV- Day 1: 16 hours postdose | 747.7 ± 32.7 |
| BRV- Day 1: 24 hours postdose | 423.8 ± 45.9 |
| BRV- Day 1: 36 hours postdose | 157.6 ± 64.4 |
| BRV- Day 1: 48 hours postdose | 68.75 ± 86.6 |
| BRV- Day 1: 72 hours postdose | 9.372 ± 229 |
| ucb-42145- Day 1: Predose | NA ± NA |
| ucb-42145- Day 1: 0.25 hour postdose | 4.480 ± 131 |
| ucb-42145- Day 1: 0.50 hour postdose | 27.48 ± 66.8 |
| ucb-42145- Day 1: 1 hour postdose | 78.18 ± 31.8 |
| ucb-42145- Day 1: 1.5 hours postdose | 130.5 ± 19.6 |
| ucb-42145- Day 1: 2 hours postdose | 155.9 ± 22.8 |
| ucb-42145- Day 1: 3 hours postdose | 187.8 ± 30.3 |
| ucb-42145- Day 1: 4 hours postdose | 149.4 ± 21.8 |
| ucb-42145- Day 1: 6 hours postdose | 122.5 ± 16.5 |
| ucb-42145- Day 1: 9 hours postdose | 112.6 ± 25.0 |
| ucb-42145- Day 1: 12 hours postdose | 75.73 ± 26.3 |
| ucb-42145- Day 1: 16 hours postdose | 59.17 ± 26.6 |
| ucb-42145- Day 1: 24 hours postdose | 37.46 ± 38.4 |
| ucb-42145- Day 1: 36 hours postdose | 12.82 ± 50.8 |
| ucb-42145- Day 1: 48 hours postdose | 6.222 ± 64.1 |
| ucb-42145- Day 1: 72 hours postdose | NA ± NA |
| ucb-100406-1- Day 1: Predose | NA ± NA |
| ucb-100406-1- Day 1: 0.25 hour postdose | 7.364 ± 146 |
| ucb-100406-1- Day 1: 0.5 hour postdose | 29.78 ± 88.5 |
| ucb-100406-1- Day 1: 1 hour postdose | 39.97 ± 81.2 |
| ucb-100406-1- Day 1: 1.5 hour postdose | 44.11 ± 78.5 |
| ucb-100406-1- Day 1: 2 hours postdose | 52.59 ± 84.7 |
| ucb-100406-1- Day 1: 3 hours postdose | 63.15 ± 83.9 |
| ucb-100406-1- Day 1: 4 hours postdose | 73.57 ± 85.1 |
| ucb-100406-1- Day 1: 6 hours postdose | 87.58 ± 85.6 |
| ucb-100406-1- Day 1: 9 hours postdose | 91.89 ± 88.2 |
| ucb-100406-1- Day 1: 12 hours postdose | 86.76 ± 88.6 |
| ucb-100406-1- Day 1: 16 hours postdose | 78.88 ± 87.0 |
| ucb-100406-1- Day 1: 24 hours postdose | 52.44 ± 86.2 |
| ucb-100406-1- Day 1: 36 hours postdose | 22.54 ± 77.8 |
| ucb-100406-1- Day 1: 48 hours postdose | 10.35 ± 72.1 |
| ucb-100406-1- Day 1: 72 hours postdose | NA ± NA |
| ucb107092-1- Day 1: Predose | NA ± NA |
| ucb107092-1- Day 1: 0.25 hour postdose | NA ± NA |
| ucb107092-1- Day 1: 0.5 hour postdose | NA ± NA |
| ucb107092-1- Day 1: 1 hour postdose | 4.404 ± 62.9 |
| ucb107092-1- Day 1: 1.5 hours postdose | 9.800 ± 32.1 |
| ucb107092-1- Day 1: 2 hours postdose | 16.17 ± 22.6 |
| ucb107092-1- Day 1: 3 hours postdose | 27.06 ± 18.3 |
| ucb107092-1- Day 1: 4 hours postdose | 37.89 ± 22.1 |
| ucb107092-1- Day 1: 6 hours postdose | 41.59 ± 16.3 |
| ucb107092-1- Day 1: 9 hours postdose | 38.77 ± 25.1 |
| ucb107092-1- Day 1: 12 hours postdose | 28.37 ± 20.8 |
| ucb107092-1- Day 1: 16 hours postdose | 21.85 ± 22.0 |
| ucb107092-1- Day 1: 24 hours postdose | 14.49 ± 28.7 |
| ucb107092-1- Day 1: 36 hours postdose | 6.443 ± 23.4 |
| ucb107092-1- Day 1: 48 hours postdose | 3.976 ± 29.0 |
| ucb107092-1- Day 1: 72 hours postdose | NA ± NA |
| ng/mL | Brivaracetam |
|---|---|
| BRV- Day 5: Predose | NA ± NA |
| BRV- Day 6: Predose | 1743 ± 33.6 |
| BRV- Day 7: Predose | 1981 ± 36.3 |
| BRV- Day 8: Predose | 1955 ± 38.4 |
| BRV- Day 9: Predose | 1975 ± 41.7 |
| BRV- Day 10: Predose | 1918 ± 34.2 |
| BRV- Day 10: 0.25 hour postdose | 2888 ± 54.0 |
| BRV- Day 10: 0.5 hour postdose | 4582 ± 45.6 |
| BRV- Day 10: 1 hour postdose | 4448 ± 30.2 |
| BRV- Day 10: 1.5 hour postdose | 4583 ± 21.5 |
| BRV- Day 10: 2 hours postdose | 4421 ± 22.1 |
| BRV- Day 10: 3 hours postdose | 4037 ± 23.3 |
| BRV- Day 10: 4 hours postdose | 3671 ± 26.2 |
| BRV- Day 10: 6 hours postdose | 2956 ± 26.7 |
| BRV- Day 10: 9 hours postdose | 2241 ± 32.4 |
| BRV- Day 10: 12 hours postdose | 1702 ± 38.4 |
| BRV- Day 10: 16 hours postdose | 1185 ± 44.1 |
| BRV- Day 10: 24 hours postdose | 614.7 ± 57.6 |
| BRV- Day 10: 36 hours postdose | 216.1 ± 75.3 |
| BRV- Day 10: 48 hours postdose | 93.68 ± 95.8 |
| BRV- Day 10: 72 hours postdose | 17.75 ± 154 |
| ucb-42145- Day 5: Predose | NA ± NA |
| ucb-42145- Day 6: Predose | 153.6 ± 25.7 |
| ucb-42145- Day 7: Predose | 185.8 ± 26.0 |
| ucb-42145- Day 8: Predose | 181.1 ± 28.1 |
| ucb-42145- Day 9: Predose | 193.1 ± 34.1 |
| ucb-42145- Day 10: Predose | 166.6 ± 34.9 |
| ucb-42145- Day 10: 0.25 hour postdose | 156.1 ± 38.3 |
| ucb-42145- Day 10: 0.5 hour postdose | 177.0 ± 35.6 |
| ucb-42145- Day 10: 1 hour postdose | 247.8 ± 34.5 |
| ucb-42145- Day 10: 1.5 hour postdose | 265.2 ± 28.5 |
| ucb-42145- Day 10: 2 hours postdose | 293.2 ± 26.2 |
| ucb-42145- Day 10: 3 hours postdose | 357.2 ± 21.1 |
| ucb-42145- Day 10: 4 hours postdose | 291.6 ± 27.0 |
| ucb-42145- Day 10: 6 hours postdose | 199.9 ± 24.2 |
| ucb-42145- Day 10: 9 hours postdose | 185.1 ± 28.4 |
| ucb-42145- Day 10: 12 hours postdose | 123.7 ± 32.3 |
| ucb-42145- Day 10: 16 hours postdose | 111.4 ± 33.7 |
| ucb-42145- Day 10: 24 hours postdose | 54.35 ± 42.9 |
| ucb-42145- Day 10: 36 hours postdose | 17.39 ± 59.5 |
| ucb-42145- Day 10: 48 hours postdose | 9.114 ± 67.4 |
| ucb-42145- Day 10: 72 hours postdose | NA ± NA |
| ucb-100406-1- Day 5: Predose | NA ± NA |
| ucb-100406-1- Day 6: Predose | 146.9 ± 78.9 |
| ucb-100406-1- Day 7: Predose | 188.1 ± 75.4 |
| ucb-100406-1- Day 8: Predose | 209.2 ± 72.1 |
| ucb-100406-1- Day 9: Predose | 217.0 ± 71.3 |
| ucb-100406-1- Day 10: Predose | 218.2 ± 71.8 |
| ucb-100406-1- Day 10: 0.25 hour postdose | 221.2 ± 70.8 |
| ucb-100406-1- Day 10: 0.5 hour postdose | 238.2 ± 67.6 |
| ucb-100406-1- Day 10: 1 hour postdose | 243.9 ± 67.5 |
| ucb-100406-1- Day 10: 1.5 hours postdose | 258.2 ± 70.9 |
| ucb-100406-1- Day 10: 2 hours postdose | 249.9 ± 67.8 |
| ucb-100406-1- Day 10: 3 hours postdose | 248.3 ± 69.1 |
| ucb-100406-1- Day 10: 4 hours postdose | 254.3 ± 70.9 |
| ucb-100406-1- Day 10: 6 hours postdose | 238.7 ± 68.7 |
| ucb-100406-1- Day 10: 9 hours postdose | 229.0 ± 70.1 |
| ucb-100406-1- Day 10: 12 hours postdose | 212.2 ± 76.0 |
| ucb-100406-1- Day 10: 16 hours postdose | 171.7 ± 73.1 |
| ucb-100406-1- Day 10: 24 hours postdose | 111.6 ± 72.8 |
| ucb-100406-1- Day 10: 36 hours postdose | 41.71 ± 72.8 |
| ucb-100406-1- Day 10: 48 hours postdose | 19.41 ± 66.7 |
| ucb-100406-1- Day 10: 72 hours postdose | 2.771 ± 75.0 |
| ucb107092-1- Day 5: Predose | NA ± NA |
| ucb107092-1- Day 6: Predose | 51.71 ± 22.0 |
| ucb107092-1- Day 7: Predose | 63.87 ± 27.2 |
| ucb107092-1- Day 8: Predose | 65.14 ± 25.5 |
| ucb107092-1- Day 9: Predose | 71.64 ± 23.3 |
| ucb107092-1- Day 10: Predose | 68.47 ± 23.8 |
| ucb107092-1- Day 10: 0.25 hour postdose | 62.74 ± 21.9 |
| ucb107092-1- Day 10: 0.5 hour postdose | 63.76 ± 19.6 |
| ucb107092-1- Day 10: 1 hour postdose | 65.20 ± 20.0 |
| ucb107092-1- Day 10: 1.5 hours postdose | 68.84 ± 22.1 |
| ucb107092-1- Day 10: 2 hours postdose | 71.72 ± 18.9 |
| ucb107092-1- Day 10: 3 hours postdose | 82.18 ± 20.2 |
| ucb107092-1- Day 10: 4 hours postdose | 84.04 ± 15.2 |
| ucb107092-1- Day 10: 6 hours postdose | 80.87 ± 20.2 |
| ucb107092-1- Day 10: 9 hours postdose | 69.25 ± 23.6 |
| ucb107092-1- Day 10: 12 hours postdose | 52.96 ± 17.8 |
| ucb107092-1- Day 10: 16 hours postdose | 42.69 ± 21.1 |
| ucb107092-1- Day 10: 24 hours postdose | 28.57 ± 25.4 |
| ucb107092-1- Day 10: 36 hours postdose | 13.15 ± 26.1 |
| ucb107092-1- Day 10: 48 hours postdose | 8.580 ± 32.0 |
| ucb107092-1- Day 10: 72 hours postdose | 3.380 ± 52.9 |
AUC(0-t) was defined as the area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification.
| hours*nanograms per milliliter (h*ng/mL) | Brivaracetam |
|---|---|
| Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measured Concentration Above the Limit of Quantification (AUC(0-t)) of Brivaracetam for Single Dose | 35730 ± 28.7 |
Cmax was defined as the maximum observed plasma concentration.
| ng/mL | Brivaracetam |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Brivaracetam for Single Dose | 3334 ± 22.2 |
AUC(0-12),ss was defined as the area under the plasma concentration-time curve from 0 to 12 hours at steady state.
| h*ng/mL | Brivaracetam |
|---|---|
| Area Under the Plasma Concentration-time Curve From 0 to 12 Hours at Steady State (AUC(0-12),ss) of Brivaracetam for Multiple Dose | 36760 ± 27.8 |
Cmax,ss was defined as the maximum plasma concentration at steady state.
| ng/mL | Brivaracetam |
|---|---|
| Maximum Plasma Concentration at Steady State (Cmax,ss) of Brivaracetam for Multiple Dose | 5215 ± 27.7 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent AEs (TEAEs) were defined as those events that start on or after the time of first investigational medicinal product (IMP) administration, or whose severity worsens on or after the date of first administration of the IMP.
| Participants | Brivaracetam |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | 12 |
Tmax was defined as the time to reach maximum concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| hour | Brivaracetam |
|---|---|
| Brivaracetam | 1.000 (0.500 to 3.00) |
| ucb-42145 | 3.000 (1.50 to 6.00) |
| ucb-100406-1 | 9.000 (6.00 to 12.0) |
| ucb107092-1 | 6.000 (4.00 to 9.00) |
t1/2 was defined as the terminal elimination half-life. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| hour | Brivaracetam |
|---|---|
| Brivaracetam | 9.628 ± 2.229 |
| ucb-42145 | 10.40 ± 2.716 |
| ucb-100406-1 | 10.24 ± 1.696 |
| ucb107092-1 | 12.38 ± 1.019 |
λz was defined as the rate constant of elimination. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| 1/hour | Brivaracetam |
|---|---|
| Brivaracetam | 0.07370 ± 22.7 |
| ucb-42145 | 0.06866 ± 25.3 |
| ucb-100406-1 | 0.06847 ± 15.9 |
| ucb107092-1 | 0.05614 ± 8.10 |
MRT was defined as the mean residence time.
| hour | Brivaracetam |
|---|---|
| Mean Residence Time (MRT) of Brivaracetam in Plasma for Single Dose | 13.02 ± 18.8 |
AUC was defined as the area under the plasma concentration-time curve from 0 to infinite time. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| h*ng/mL | Brivaracetam |
|---|---|
| Brivaracetam | 36000 ± 29.1 |
| ucb-42145 | 2567 ± 25.4 |
| ucb-100406-1 | 2530 ± 81.5 |
| ucb107092-1 | 878.2 ± 21.1 |
CL/F was defined as the apparent total body clearance.
| Liter per hour (L/h) | Brivaracetam |
|---|---|
| Apparent Total Body Clearance (CL/F) of Brivaracetam in Plasma for Single Dose | 2.777 ± 29.1 |
Vz/F was defined as the apparent volume of distribution.
| Liter | Brivaracetam |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Brivaracetam in Plasma for Single Dose | 37.69 ± 10.8 |
Cmax was defined as the maximum plasma concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| ng/mL | Brivaracetam |
|---|---|
| ucb-42145 | 193.3 ± 27.7 |
| ucb-100406-1 | 93.16 ± 88.0 |
| ucb107092-1 | 43.18 ± 21.1 |
AUC(0-t) was defined as the area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| h*ng/mL | Brivaracetam |
|---|---|
| ucb-42145 | 2503 ± 25.4 |
| ucb-100406-1 | 2423 ± 85.2 |
| ucb107092-1 | 799.2 ± 21.1 |
tmax is the time to reach maximum plasma concentration. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| hour | Brivaracetam |
|---|---|
| Brivaracetam | 0.5000 (0.250 to 2.00) |
| ucb-42145 | 3.000 (2.00 to 4.00) |
| ucb-100406-1 | 1.500 (1.00 to 6.00) |
| ucb107092-1 | 4.000 (0.00 to 6.02) |
t1/2 is the terminal elimination half-life. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| hour | Brivaracetam |
|---|---|
| Brivaracetam | 10.25 ± 1.749 |
| ucb-42145 | 10.15 ± 2.198 |
| ucb-100406-1 | 9.645 ± 1.067 |
| ucb107092-1 | 14.85 ± 2.334 |
λz is the rate constant of elimination. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| 1/hour | Brivaracetam |
|---|---|
| Brivaracetam | 0.06860 ± 17.9 |
| ucb-42145 | 0.06984 ± 22.4 |
| ucb-100406-1 | 0.07228 ± 11.3 |
| ucb107092-1 | 0.04721 ± 16.5 |
Cmin,ss is the minimum plasma concentration at steady state.
| ng/mL | Brivaracetam |
|---|---|
| Minimum Plasma Concentration at Steady State (Cmin,ss) of Brivaracetam in Plasma for Multiple Dose | 1696 ± 38.2 |
Cav,ss is the average plasma concentration at steady state.
| ng/mL | Brivaracetam |
|---|---|
| Average Plasma Concentration at Steady State (Cav,ss) of Brivaracetam in Plasma for Multiple Dose | 3064 ± 27.8 |
CLss/F is the apparent total body clearance at steady state.
| L/h | Brivaracetam |
|---|---|
| Apparent Total Body Clearance at Steady State (CLss/F) of Brivaracetam in Plasma for Multiple Dose | 2.720 ± 27.8 |
Vz/F is the apparent volume of distribution.
| Liter | Brivaracetam |
|---|---|
| Vz/F of Brivaracetam in Plasma for Multiple Dose | 39.65 ± 14.8 |
Cmax,ss is the maximum plasma concentration at steady state. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| ng/mL | Brivaracetam |
|---|---|
| ucb-42145 | 357.9 ± 21.6 |
| ucb-100406-1 | 264.8 ± 68.8 |
| ucb107092-1 | 88.53 ± 16.1 |
AUC(0-12),ss is the area under the curve from 0 to 12 hours at steady state. ucb-42145, ucb-100406-1, and ucb107092-1 are the metabolites of brivaracetam.
| h*ng/mL | Brivaracetam |
|---|---|
| ucb-42145 | 2644 ± 23.5 |
| ucb-100406-1 | 2844 ± 70.0 |
| ucb107092-1 | 867.1 ± 18.3 |
PTF was calculated as (Cmax,ss-Cmin,ss)/Cav,ss.
| ratio | Brivaracetam |
|---|---|
| Peak Trough Fluctuation (PTF) of Brivaracetam in Steady-state for Multiple Dose | 1.131 ± 24.2 |
Accumulation ratio (RAUC) was calculated as AUC(0-12),ss divided by AUC(0-12).
| ratio | Brivaracetam |
|---|---|
| Accumulation Ratio Calculated From AUC at Steady State and AUC After Single Dose (RAUC) of Brivaracetam for Multiple Dose | 1.677 ± 12.6 |
Accumulation ratio (Rmax) was calculated as Cmax,ss divided by Cmax.
| ratio | Brivaracetam |
|---|---|
| Accumulation Ratio Calculated From Cmax at Steady State and Cmax After Single Dose (Rmax) of Brivaracetam for Multiple Dose | 1.564 ± 30.4 |
Collected over From Day 1 to the end of Safety Follow-up (approximately 6 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brivaracetam | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| Event | Brivaracetam |
|---|---|
| DizzinessNervous system disorders | 10/12 |
| SomnolenceNervous system disorders | 7/12 |
| DiarrhoeaGastrointestinal disorders | 4/12 |
| AstheniaGeneral disorders | 3/12 |
| Electrocardiogram QT prolongedInvestigations | 3/12 |
| AtaxiaNervous system disorders | 3/12 |
| NeutrophiliaBlood and lymphatic system disorders | 1/12 |
| Atrioventricular block first degreeCardiac disorders | 1/12 |
| Ventricular extrasystolesCardiac disorders | 1/12 |
| PalpitationsCardiac disorders | 1/12 |
The Safety Set consisted of all participants who received at least 1 dose of BRV.
| Age, Categorical(Participants) | Brivaracetam |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 12 |
| >=65 years | 0 |
| Age, Continuous(years) | Brivaracetam |
|---|---|
| Mean | 29.9 ± 7.4 |
| Sex: Female, Male(Participants) | Brivaracetam |
|---|---|
| Female | 6 |
| Male | 6 |
| Race/Ethnicity, Customized(Participants) | Brivaracetam |
|---|---|
| Asian | 12 |
| Race/Ethnicity, Customized(Participants) | Brivaracetam |
|---|---|
| Not Hispanic or Latino | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.
Ran from May 2021 to primary completion in Jun 2021, 0 months.
Results were first posted in Mar 2023, 1 year 9 months after primary completion.
Of 34 industry-sponsored phase 1 interventional studies under Epilepsy, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 0 months is below that.
Counting every sponsor, half of 55 studies reached it within 8 months; a quarter within 3 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam